We also connected with North Carolina-based Aerami Therapuetics (formerly Dance Pharmaceuticals), which is working on a next-generation inhalable insulin product. Theirs is a fine mist aerosol formulation instead of a powder, delivered by their new inhaler device called AFINA. It will have built-in Bluetooth capability to track data and integrate with apps and platforms. The company has completed seven early stage trials to date, and is now looking for a partner for their phase 3 study design with the Food and Drug Administration.